UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstracts for References 2,3,50,52,60,64,71

of '化疗引起的脱发'

2
TI
A practitioner's guide to cancer-related alopecia.
AU
Dorr VJ
SO
Semin Oncol. 1998;25(5):562.
 
Alopecia due to the side effects of the treatment of cancer is one of the most common and emotionally troublesome effects of cancer therapy. Preventive measures, primarily scalp hypothermia, can be effective in some cases, but the worry of subsequent scalp metastasis remains. Investigative studies in animals are hindered by a poor animal alopecia model. Several promising agents require translation into clinical practice. Until then, disguising the alopecia with wigs, hats, or turbans remains the mainstay of treatment.
AD
Ellis Fischel Cancer Center, University of Missouri, Columbia 65203, USA.
PMID
3
TI
Chemotherapy-induced alopecia: new developments.
AU
Hussein AM
SO
South Med J. 1993;86(5):489.
 
Alopecia (hair loss) is one of the most physically and psychologically distressing side effects of cancer chemotherapeutic drugs. Since its first recognition as a common outcome to most chemotherapeutic agents, only a few trials have been reported, using either a method to temporarily reduce the scalp blood flow (scalp tourniquet or hypothermia) or vitamin E, with undocumented and variable efficacy. The lack of progress in the treatment and prevention of chemotherapy-induced alopecia is in part due to the lack of a reproducible animal model. In the past 2 years, we reported on the following observations: (1) treatment of 8-day-old rats with vidarabine (ara-C), doxorubicin, and cyclophosphamide consistently produced either total body alopecia (ara-C and cyclophosphamide) or alopecia confined to the head and proximal part of the back (doxorubicin); (2) Imuvert, a biologic response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against alopecia induced by ara-C and doxorubicin but not that produced by cyclophosphamide; (3) the protective effect of Imuvert against chemotherapy-induced alopecia is mediated by a monocyte-mediated cytokine; and (4) this monocyte-derived cytokine is, possibly, interleukin-1. These observations constitute important progress in the understanding and prevention of chemotherapy-induced alopecia.
AD
William J. Harrington Center for Blood Diseases, University of Miami School of Medicine, Fla.
PMID
50
TI
Scalp hypothermia in the prevention of chemotherapy-induced alopecia.
AU
Vendelbo Johansen L
SO
Acta Radiol Oncol. 1985;24(2):113.
 
Alopecia is a common side effect of cancer chemotherapy, especially in combination with regimens with doxorubicin (Adriamycin). The effect of scalp hypothermia in connection with chemotherapy was evaluated as hair protection in 61 women with disseminated breast carcinoma, where earlier treatment routines had caused wig-requiring alopecia in nearly all patients. The cooling was performed with a gel-helmet (Hypotherm Gel-Kap). Of the 61 patients, 47 (77%) had no or slight, not wig-demanding hair loss, and 14 (23%) had severe (wig-demanding) hair loss. Seven patients had liver dysfunction; in 5 of these severe hair loss was observed; 2 had slight hair loss. Eighty-three per cent of the patients with normal liver function had no hair loss. Treatment tolerance was found to be good, and side effects were minimal. The method is found to be simple, effective and inexpensive, though still not technically optimal.
AD
PMID
52
TI
Adriamycin alopecia prevented by cold air scalp cooling.
AU
Symonds RP, McCormick CV, Maxted KJ
SO
Am J Clin Oncol. 1986;9(5):454.
 
Preliminary studies are reported on the effectiveness of cold air scalp cooling to prevent alopecia in patients receiving Adriamycin. Cold air produced in a novel way using a vortex refrigeration tube was applied to the scalp for 15 min before and 30 min after the administration of Adriamycin and other cytotoxic agents. Sixteen of 26 patients had no hair loss, four had slight hair loss, and six required a wig. Two subgroups fared particularly well. Four of four patients treated with ABVD for Hodgkin's disease and nine of 13 treated with Adriamycin (40 mg/m2) and vincristine (2 mg) for breast cancer had no hair loss.
AD
PMID
60
TI
Prevention of chemotherapy-induced alopecia: a review of the literature.
AU
Cline BW
SO
Cancer Nurs. 1984;7(3):221.
 
AD
PMID
64
TI
Scalp hypothermia in the prevention of doxorubicin-induced hair loss.
AU
Giaccone G, Di Giulio F, Morandini MP, Calciati A
SO
Cancer Nurs. 1988;11(3):170.
 
AD
PMID
71
TI
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
AU
Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J
SO
Eur J Cancer. 1997;33(2):297.
 
Docetaxel is a new taxoid antineoplastic agent with clinical efficacy especially in breast cancer. One of the most distressing side-effects induced by docetaxel is alopecia. We studied the prevention of alopecia by using a cold cap in 98 patients receiving 100 mg/m2 docetaxel by 1 h i.v. infusion every 3 weeks. One patient was lost to follow-up. 83 patients (86%) were evaluated as a success to the cold cap, as they presented WHO grade alopecia<or = 2 and no need to wear a wig. 14 patients (14%) had to wear a wig; among them; 7 patients withdrew before the evaluation at three cycles. The cold cap is a very effective technique with minimal side-effects for docetaxel-treated patients.
AD
Centre Oscar Lambret, Lille, France.
PMID